Lipoxygenase products increase monocyte adhesion to human aortic endothelial cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 11, 1999, Pages 2615-2622

  Patricia, Mary Kim ^a   Kim, Jeong A ^a,c   Harper, Cynthia M ^a   Shih, Peggy T ^a   Berliner, Judith A ^a   Natarajan, Rama ^b   Nadler, Jerry L ^b   Hedrick, Catherine C ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

12(S) hydroxyeicosatetraenoic acid; Endothelium; Hyperglycemia; Lipoxygenase; Monocytes

Indexed keywords

BETA1 INTEGRIN; FIBRONECTIN; LIPOXYGENASE;

AORTA; ARTERY ENDOTHELIUM; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL ADHESION; CELL INTERACTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032725609     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.11.2615     Document Type: Article

References (42)

1. Steiner G. Atherosclerosis, the major complication of diabetes. Adv Exp Med Biol. 1985;189:277-297.
2. Tkác I, Kimball BP, Lewis G, Uffelman K, Steiner G. The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Arterioscler Thromb Vasc Biol. 1997;17:3633-3638.
3. Gerrity RG. The role of the monocyte in atherogenesis, I: transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981;103:181-190.
4. Hadcock S, Richardson M, Winocour PD, Hatton MW. Intimal alterations in rabbit aortas during the first 6 months of alloxan-induced diabetes. Arterioscler Thromb. 1991;11:517-529.
5. Dosquet C, Weill D, Wautier JL. Molecular mechanism of blood monocyte adhesion to vascular endothelial cells. Nouv Rev Fr Hematol. 1992;34(suppl):S55-S59.
6. Lyons TJ. Lipoprotein glycation and its metabolic consequences. Diabetes. 1992;41(suppl 2):67-73.
7. Kawamura M, Heinecke JW, Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest. 1994;94:771-778.
8. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun. 1990;173:932-939.
9. Leitinger N, Watson AD, Faull KF, Fogelman AM, Berliner JA. Monocyte binding to endothelial cells induced by oxidized phospholipids present in minimally oxidized low density lipoprotein is inhibited by a platelet activating factor receptor antagonist. Adv Exp Med Biol. 1997;433:379-382.
10. Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med. 1996;28:419-426.
11. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci U S A. 1990;87:9010-9014.
12. Kim JA, Berliner JA, Natarajan RD, Nadler JL. Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes. 1994;43:1103-1107.
13. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A. 1993;90:6434-6438.
14. Brown ML, Jakubowski JA, Leventis LL, Deykin D. Elevated glucose alters eicosanoid release from porcine aortic endothelial cells. J Clin Invest. 1988;82:2136-2141.
15. Natarajan R, Gu JL, Rossi J, Gonzales N, Lanting L, Xu L, Nadler J. Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells. Proc Natl Acad Sci U S A. 1993;90:4947-4951.
16. Baud L, Sraer J, Delarue F, Bens M, Balavoine F, Schlondorff D, Ardaillou R, Sraer JD. Lipoxygenase products mediate the attachment of rat macrophages to glomeruli in vitro. Kidney Int. 1985;27:855-863.
17. Goetzl EJ, Sun FF. Generation of unique mono-hydroxy-eicosatetraenoic acids from arachidonic acid by human neutrophils. J Exp Med. 1979;150:406-411.
18. Kimura I, Hata Y, Islam MA, Kimura M, Diabetes mellitus-induced enhancement of prostaglandin F2 α-responses is inhibited by lipoxygenase- but not cyclooxygenase-inhibitors in mesenteric veins and arteries of mouse and rat. Jpn J Pharmacol. 1994;64:65-70.
19. Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci U S A. 1989;86:1046-1050.
20. Wilkins GM, Leake DS. The effect of inhibitors of free radical generating-enzymes on low-density lipoprotein oxidation by macrophages. Biochim Biophys Acta. 1994;1211:69-78.
21. Kim JA, Gu JL, Natarajan R, Berliner JA, Nadler JL. A leukocyte type of 12-lipoxygenase is expressed in human vascular and mononuclear cells: evidence for upregulation by angiotensin II. Arterioscler Thromb Vasc Biol. 1995;15:942-948.
22. Fogelman AM, Elahi F, Sykes K, Van Lenten BJ, Territo MC, Berliner JA. Modification of the Recalde method for the isolation of human monocytes. J Lipid Res. 1988;29:1243-1247.
23. Boyurn A. Isolation of mononuclear cells and granulocytes from human blood: isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77-89.
24. Nadler JL, Natarajan R, Stern N. Specific action of the lipoxygenase pathway in mediating angiotensin II-induced aldosterone synthesis in isolated adrenal glomerulosa cells. J Clin Invest. 1987;80:1763-1769.
25. Honda H, Leitinger N, Frankel F, Goldhaber J, Natarajan R, Nadler J, Weiss J, Berliner J. Induction of monocyte binding to endothelial cells by MM-LDL: the role of the lipoxygenase metabolites. Arterioscler Thromb Vasc Biol. 1999;19:680-686.
26. Wayner EA, Garcia-Pardo A, Humphries MJ, McDonald JA, Carter WG. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol. 1989;109:1321-1330.
27. Shih PT, Elices MJ, Fang ZT, Ugarova TP, Strahl D, Territo MC, Frank JS, Kovach NL, Cabanas C, Berliner JA, Vora DK. Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating β1 integrin. J Clin Invest. 1999;103:613-625.
28. Springer TA. Adhesion receptors of the immune system. Nature. 1990;346:425-434.
29. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol. 1993;11:767-804.
30. Sultana C, Shen Y, Rattan V, Kalra VK. Lipoxygenase metabolites induced expression of adhesion molecules and transendothelial migration of monocyte-like HL-60 cells is linked to protein kinase C activation. J Cell Physiol. 1996;167:477-487.
31. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, Lobb RR. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell. 1990;60:577-584.
32. Guan JL, Hynes RO. Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor α4 β1. Cell. 1990;60:53-61.
33. McEver RP. Leukocyte-endothelial cell interactions. Curr Opin Cell Biol. 1992;4:840-849.
34. Chopra H, Timar J, Chen YQ, Rong XH, Grossi IM, Fitzgerald LA, Taylor JD, Honn KV. The lipoxygenase metabolite 12(S)-HETE induces a cytoskeleton-dependent increase in surface expression of integrin αIIb β3 on melanoma cells. Int J Cancer. 1991;49:774-786.
35. Tang DG, Diglio CA, Bazaz R, Honn KV. Transcriptional activation of endothelial cell integrin αv by protein kinase C activator 12(S)-HETE. J Cell Sci. 1995;108:2629-2644.
36. Trikha M, Honn KV. Role of 12-lipoxygenase and protein kinase C in modulating the activation state of the integrin αIIb β3 on human tumor cells. Adv Exp Med Biol. 1997;407:55-60.
37. Wang LX, Kaduce TL, Spector AA. Localization of 12-hydroxyeicosatetraenoic acid in endothelial cells. J Lipid Res. 1990;31:2265-2276.
38. Gross E, Ruzicka T, von Restorff B, Stolz W, Klotz KN. High-affinity binding and lack of growth-promoting activity of 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) in a human epidermal cell line. J Invest Dermatol. 1990;94:446-451.
39. Herbertsson H, Hammarström S. High-affinity binding sites for 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid (12(S)-HETE) in carcinoma cells. FEBS Lett. 1992;298:249-252.
40. Wainwright SL, Powell WS. Mechanism for the formation of dihydro metabolites of 12-hydroxyeicosanoids: conversion of leukotriene B4 and 12-hydroxy-5,8,10,14-eicosatetraenoic acid to 12-oxo intermediates. J Biol Chem. 1991;266:20899-20906.
41. Murphy RC, Falck JR, Lumin S, Yadagiri P, Zirrolli JA, Balazy M, Masferrer JL, Abraham NG, Schwartzman ML. 12(R)-Hydroxyeicosatrienoic acid: a vasodilator cytochrome P-450-dependent arachidonate metabolite from the bovine comeal epithelium. J Biol Chem. 1988;263:17197-17202.
42. Henricks PA, Engels F, van der Vliet H, Nijkamp FP. 9- and 13-Hydroxylinoleic acid possess chemotactic activity for bovine and human polymorphonuclear leukocytes. Prostaglandins. 1991;41:21-27.